Omnicell, Inc. (OMCL) Stock Price & How to Invest

Omnicell, Inc. (NASDAQ: OMCL) is a healthcare-technology company that builds medication-management and pharmacy-automation systems for hospitals, health systems, retail and specialty pharmacies, and other care settings. Its core products include automated dispensing cabinets (the XT and XR series), central-pharmacy robotics, IV compounding automation, and a growing layer of cloud software and services branded around what the company calls the Autonomous Pharmacy. Omnicell earns money from product sales (the hardware and installed systems) and from a rising base of recurring service and subscription revenue, including its Advanced Services and technician-enabled offerings, and it tracks annual recurring revenue (ARR) and product bookings as key operating metrics.

The investment picture is a turnaround-and-transition story. After a pandemic-era boom and a subsequent slump in hospital capital spending, Omnicell has been steering its mix toward higher-margin recurring revenue while stabilizing its hardware business. Full-year 2025 revenue was about $1.185 billion, up roughly 7% from 2024, with non-GAAP EBITDA of about $140 million, and the company guided 2026 revenue toward roughly $1.215 billion to $1.255 billion. In the first quarter of 2026 revenue grew about 15% year over year to about $310 million, and the company raised its full-year non-GAAP EPS guidance, signaling improving profitability. The bull case rests on ARR growth, expanding margins, and a large installed base of hospital customers; the bear case reflects reliance on cyclical hospital capital budgets, competition from larger rivals, and a GAAP earnings base that has been depressed relative to the share price.

Omnicell's product revenue depends heavily on hospital and health-system capital budgets, which are cyclical and can be cut quickly when providers face financial pressure, making bookings and revenue lumpy. It competes against larger and better-capitalized rivals, most notably BD (Becton Dickinson) with its Pyxis dispensing line, along with Baxter, Swisslog, and other automation vendors, which can pressure pricing and market share. The company's GAAP profitability has at times been thin relative to its share price, so a large gap between GAAP and non-GAAP earnings and a high trailing P/E leave little room for execution missteps. Long installation and implementation cycles, customer concentration among big health systems, and integration risk from acquisitions add operational uncertainty. Broader healthcare-policy shifts, reimbursement pressure, supply-chain costs, and any product-reliability or regulatory issues around medication safety could also weigh on results.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Omnicell, Inc.'s investor relations page or your broker.

• Revenue (FY2025): ~$1.185 billion (up ~7%)
• Non-GAAP EBITDA (FY2025): ~$140 million
• Revenue (Q1 2026): ~$310 million (up ~15% YoY)
• Non-GAAP EPS (Q1 2026): ~$0.55 (vs ~$0.26 a year earlier)
• FY2026 Revenue Guidance: ~$1.215-1.255 billion
• FY2026 Non-GAAP EPS Guidance: ~$1.80-2.00
• Market Capitalization: ~$1.96 billion (July 2026)
• Share Price / 52-Week Range: ~$43, range ~$26.85-$55.00

Omnicell trades around $43 per share for a market capitalization near $1.96 billion as of July 2026, with a wide 52-week range that reflects how sensitive the stock is to bookings and margin trends. The trailing GAAP P/E has been very high (around 97) because GAAP earnings have been depressed, while normalized or forward multiples on non-GAAP EPS are far lower (Morningstar cited a normalized P/E near 22). That gap between GAAP and non-GAAP earnings is central to how different investors value the name.

There are three common ways to get OMCL exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so OMCL sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where OMCL fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Omnicell is a mid-cap pharmacy-automation company working through a transition from lumpy hardware sales toward recurring software and service revenue, with 2025 revenue of about $1.185 billion and a return to double-digit growth in early 2026, and it trades and moves like a cyclical, execution-sensitive healthcare-tech name.

Whether OMCL is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is OMCL a buy?, and where the stock could go from here in the OMCL stock forecast.

For income investors, whether OMCL pays a dividend and how the payout looks is covered in does OMCL pay a dividend?